University of Colorado Cancer Center

Anschutz Cancer Pavilion

Aurora, CO

Accepting patients

CAMMA-2

A Study Evaluating the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen (BCMA)-Exposed Participants With Relapsed/Refractory Multiple Myeloma (CAMMA 2)
Learn more
  • Bispecific Antibody
  • FCRH5
  • Phase 1/2

Accepting patients

CaMMouflage

A Phase 1, Multicenter, Open-Label Study of CB-011, a CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma (CaMMouflage Trial)
Learn more
  • CAR T Cell (Allogeneic)
  • BCMA
  • Phase 1

Not currently accepting

Cevostamab

Dose-Escalation Study of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma
Learn more
  • Bispecific Antibody
  • FCRH5
  • Phase 1
  • Has results
3 hidden based on your filters. Show All